Clinical Trial Detail

NCT ID NCT03792841
Title Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 160 in Subjects With mCRPC
Recruitment Recruiting
Gender male
Phase Phase I
Variant Requirements No
Sponsors Amgen
Indications

prostate cancer

Therapies

AMG 160 + Pembrolizumab

AMG 160

Age Groups: senior adult

No variant requirements are available.